Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Wungki Park"'
Autor:
Diana Saravia, Andrew J. Plodkowski, Annapaola Mariniello, Benjamin Besse, Lizza E.L. Hendriks, Maria Lucia Reale, Fabrizio Tabbò, Gilberto Lopes, Lydie Cassard, Anne-Marie C. Dingemans, Kathryn C. Arbour, Matthew D. Hellmann, Margarita Majem, Hira Rizvi, Edouard Auclin, Jeffrey Girshman, Silvia Novello, M. Naigeon, Simona Carnio, Nathalie Cozic, F. Blanc-Durand, Laura Mezquita, Clarisse Audigier-Valette, Peter Sawan, Paolo Bironzo, Nathalie Chaput, Jose Carlos Ruffinelli, Luis Paz-Ares, Patricia Martin-Romano, Ernest Nadal, Melinda Charrier, Wungki Park, Isabel Ruth Preeshagul, David Planchard, Santiago Ponce, Gérard Zalcman, Caroline Rossoni
Publikováno v:
EUROPEAN JOURNAL OF CANCER
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Instituto de Salud Carlos III (ISCIII)
European Journal of Cancer, 151, 211-220. ELSEVIER SCI LTD
European Journal of Cancer, 151, 211-220. Elsevier Ltd.
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Instituto de Salud Carlos III (ISCIII)
European Journal of Cancer, 151, 211-220. ELSEVIER SCI LTD
European Journal of Cancer, 151, 211-220. Elsevier Ltd.
Background: dNLR at the baseline (B), defined by neutrophils/[leucocytes-neutrophils], correlates with immune-checkpoint inhibitor (ICI) outcomes in advanced non-small-cell lung cancer (aNSCLC). However, dNLR is dynamic under therapy and its longitud
Publikováno v:
Cancer Metastasis Rev
Pancreas ductal adenocarcinoma (PDAC) is the third most common cause of cancer death in the USA. While other cancers with historically poor prognoses have benefited from new immunotherapies and targeted agents, the 5-year survival rate for PDAC patie
Autor:
Laura L. Carter, Jack Shiansong Li, Beatrice Ferguson, Wells A. Messersmith, Wungki Park, Johanna C. Bendell, Jean-Marie Bruey, Lei Zhou, Jakob Dupont, Marya F. Chaney, Drew W. Rasco, Johann S. de Bono, Andrea Wang-Gillam
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background GB1275 is a first-in-class CD11b modulator that reduced myeloid-derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs), repolarized M2 immunosuppressive TAMs to an M1 phenotype, and increased tumor infiltration of activat
Publikováno v:
JAMA
IMPORTANCE: Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer, with approximately 60 430 new diagnoses expected in 2021 in the US. The incidence of PDAC is increasing by 0.5% to 1.0% per year, and it is projected to become the s
Autor:
Deukwoo Kwon, Jaime R. Merchan, Ty K. Subhawong, Breelyn A. Wilky, Matteo Trucco, Vaia Florou, Jonathan C. Trent, Eric D. Wieder, Andrew E. Rosenberg, Darcy A. Kerr, Despina Kolonias, Efrosyni Sfakianaki, Krishna V. Komanduri, Mark Foley, Wungki Park
Publikováno v:
The Lancet. Oncology. 20(6)
Summary Background VEGF promotes an immunosuppressive microenvironment and contributes to immune checkpoint inhibitor resistance in cancer. We aimed to assess the activity of the VEGF receptor tyrosine-kinase inhibitor axitinib plus the anti-PD-1 imm
Autor:
Eileen M. O'Reilly, Debbie Slee, Jack Shiansong Li, Beatrice Ferguson, Wungki Park, Laura L. Carter, Marya F. Chaney, Andrea Wang-Gillam, Jakob Dupont, Lei Zhou, David C. Nickle, Drew W. Rasco, Johanna C. Bendell, Rebecca Tran, Wells A. Messersmith, David G. DeNardo, Anna Galkin, Luisa Salter-Cid, Vineet Gupta
Publikováno v:
Cancer Research. 80:CT247-CT247
Background: Tumor influx of CD11b-expressing myeloid-derived suppressor cells (MDSCs) and M2 tumor-associated macrophages (TAMs) creates an immunosuppressive tumor microenvironment associated with resistance to anti-PD-1 antibody therapy. GB1275 is a
Publikováno v:
Journal of Clinical Oncology. 38:TPS4667-TPS4667
TPS4667 Background: Combinations of folinic acid, fluorouracil (5-FU), irinotecan, and oxaliplatin (FOLFIRINOX) along with GN are standard first-line treatment options for mPC. Despite treatment advances, mPC has a poor prognosis with a 5-year surviv
Autor:
Muhammad Husnain, Wungki Park, Juan Carlos Ramos, Arvind Dasari, Peter J. Hosein, Raja Mudad, Joseph M. Chan, Thomas E. Johnson
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-5 (2018)
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-5 (2018)
Background Immune checkpoint inhibitors (CPIs) have shown promising results in many solid tumors. There are limited data on the safety and efficacy of these drugs in HIV infected patients as they have traditionally been excluded from CPIs clinical tr
Autor:
Pedro Nazareth Aguiar, Gilberto Lopes, Auro Del Giglio, Pui San Tan, Benjamin Haaland, Wungki Park
Publikováno v:
JAMA oncology. 4(8)
Importance The survival of patients with advanced non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations has improved substantially in the last decade with the development of targeted tyrosine kinase inhibito
Autor:
Lydia Koenig, Wungki Park, Daniel Rycroft, Yuxiang Wang, Dong M. Shin, Sujin Yun, Steve Holmes, Sreenivas Nannapaneni, Hyung Ju C. Shin, Michael Steward, Thil Batuwangala, Hongzheng Zhang, Mourad Tighiouart, Lin Pan, Zhuo Georgia Chen
Publikováno v:
International Journal of Cancer. 131:956-969
An antibody simultaneously targeting epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), two major tumor growth-driving machineries, may provide a novel effective strategy for optimizing tumor targeting and maximizi